Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 14/20 | 0.42 |
| ▸ | NTRK2 | Q16620 | 10/20 | 0.42 |
| ▸ | NTRK3 | Q16288 | 8/20 | 0.42 |
| ▸ | JAK2 | O60674 | 3/20 | 0.42 |
| ▸ | INSR | P06213 | 3/20 | 0.42 |
| ▸ | LYN | P07948 | 3/20 | 0.42 |
| ▸ | RET | P07949 | 3/20 | 0.42 |
| ▸ | MET | P08581 | 3/20 | 0.42 |
| ▸ | ROS1 | P08922 | 3/20 | 0.42 |
| ▸ | FGR | P09769 | 3/20 | 0.42 |
| ▸ | KIT | P10721 | 3/20 | 0.42 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.42 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.42 |
| ▸ | TIE1 | P35590 | 3/20 | 0.42 |
| ▸ | KDR | P35968 | 3/20 | 0.42 |
| ▸ | FLT3 | P36888 | 3/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL464595 | 0.84 | NTRK1 (0.61) | NTRK1NTRK2NTRK3JAK2INSR | |
| SCHEMBL430858 | 0.84 | NTRK1 (0.61) | NTRK1NTRK2NTRK3JAK2INSR | |
| SCHEMBL432729 | 0.83 | NTRK1 (0.61) | NTRK1NTRK2NTRK3JAK2INSR | |
| SCHEMBL430985 | 0.83 | NTRK1 (0.45) | NTRK1NTRK2NTRK3JAK2INSR | |
| SCHEMBL469746 | 0.83 | NTRK1 (0.41) | NTRK1NTRK2NTRK3JAK2INSR | |
| SCHEMBL433115 | 0.83 | NTRK1 (0.41) | NTRK1NTRK2NTRK3JAK2INSR | |
| SCHEMBL432119 | 0.82 | NTRK1 (0.49) | NTRK1NTRK2NTRK3JAK2INSR | |
| SCHEMBL431616 | 0.81 | NTRK1 (0.47) | NTRK1NTRK2NTRK3JAK2INSR | |
| SCHEMBL464572 | 0.81 | NTRK1 (0.47) | NTRK1NTRK2NTRK3JAK2INSR | |
| SCHEMBL464567 | 0.81 | NTRK1 (0.47) | NTRK1NTRK2NTRK3JAK2INSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637516-B2 | Compounds and compositions as TRK inhibitors | IRM LLC (BM) | 2014-01-28 | — | — | US | claimed |
| EP-2614062-A1 | IMIDAZO [1, 2]PYRIDAZIN COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2013-07-17 | — | — | EP | claimed |
| US-20120065184-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-03-15 | — | — | US | claimed |
| WO-2012034091-A1 | IMIDAZO [1, 2] PYRIDAZIN COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-03-15 | — | — | WO | claimed |
| US-8637516-B2 | Compounds and compositions as TRK inhibitors | IRM LLC (BM) | 2014-01-28 | — | — | US | disclosed |
| US-8637516-B2 | Compounds and compositions as TRK inhibitors | IRM LLC (BM) | 2014-01-28 | — | — | US | disclosed |
| US-8637516-B2 | Compounds and compositions as TRK inhibitors | IRM LLC (BM) | 2014-01-28 | — | — | US | disclosed |
| EP-2614062-A1 | IMIDAZO [1, 2]PYRIDAZIN COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2013-07-17 | — | — | EP | disclosed |
| US-20120065184-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-03-15 | — | — | US | disclosed |
| US-20120065184-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-03-15 | — | — | US | disclosed |
| US-20120065184-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-03-15 | — | — | US | disclosed |
| WO-2012034091-A1 | IMIDAZO [1, 2] PYRIDAZIN COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-03-15 | — | — | WO | disclosed |
| WO-2012034091-A1 | IMIDAZO [1, 2] PYRIDAZIN COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065184-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | TNK2, CNKSR1, BMP2K | NTRK1 131/4885NTRK2 64/4885NTRK3 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.